NCT00688038 is a Phase 4 clinical trial of Laser Ablation in Advanced Cancer, sponsored by M.D. Anderson Cancer Center.

Who is sponsoring NCT00688038?

NCT00688038 is sponsored by M.D. Anderson Cancer Center.

What drugs are being tested in NCT00688038?

Interventions in NCT00688038: Laser Ablation, Magnetic Resonance Thermal Imaging.

What condition does NCT00688038 study?

NCT00688038 studies Advanced Cancer, Bone Metastases.

Is NCT00688038 still recruiting?

NCT00688038 is currently completed. Last updated 15 September 2017.

Last reviewed 2017-09-15 · How we verify

NCT00688038

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Correlation of MR Thermal Imaging to Actual Size of Ablation During Laser Ablation Therapy

Completed Phase 4 Last updated 15 September 2017

What this trial tests

Phase 4 trial testing Laser Ablation in Advanced Cancer in 24 participants. Completed in 12 September 2017.

Timeline

13 May 2008

Primary endpoint
12 September 2017

12 September 2017

Quick facts

Lead sponsor	M.D. Anderson Cancer Center
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	24
Start date	13 May 2008
Primary completion	12 September 2017
Estimated completion	12 September 2017
Sites	1 location across United States

Drugs / interventions tested

Laser Ablation
Magnetic Resonance Thermal Imaging

Conditions studied

Advanced Cancer — all drugs for Advanced Cancer →
Bone Metastases — all drugs for Bone Metastases →

Sponsor

M.D. Anderson Cancer Center — full company profile →

Who can join

18 and older, any sex, with Advanced Cancer or Bone Metastases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical research study is to learn how well magnetic resonance thermal imaging (MRTI) can check the amount of tumor being destroyed using a therapy called laser ablation (a procedure that uses lasers to create heat that is designed to destroy cancer cells).

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Laser Ablation

Trials testing the same drug.

NCT03707925 — Bronchoscopic Laser Ablation of Peripheral Lung Tumors · NA · terminated

Other recruiting trials for Advanced Cancer

Currently open trials in the same condition.

NCT07393529 — A Pilot Randomized Controlled Trial of a Social Network Intervention · NA · recruiting
NCT07382544 — Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss · Phase 1 · recruiting
NCT07246954 — A Chaplain-clinician Led Spiritual Care (PEACE) Intervention on Spiritual/Religious Beliefs Related to Medical Care in P · NA · recruiting
NCT06346197 — Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas · Phase 3 · recruiting
NCT07147023 — Better Real-time Information on Documentation of Goals of Care for Engagement in Serious Illness Communication · NA · active not recruiting

Other M.D. Anderson Cancer Center trials

Trials by the same sponsor.

NCT07053020 — A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukem · Phase 1, PHASE2 · not yet recruiting
NCT07052994 — A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and · Phase 1 · not yet recruiting
NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
NCT07162480 — Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Ca · Phase 2 · not yet recruiting
NCT07076498 — Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standar · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00688038 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by M.D. Anderson Cancer Center
Last refreshed: 15 September 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00688038.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing